Singapore, June 13 -- South Korea-based Mezzion Pharma Co., a leader in rare disease therapeutics, has announced the expansion of its udenafil pipeline with the initiation of a pre-clinical study for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

This initiative builds on Mezzion's rare disease expertise in cardiovascular and hepatic conditions and marks a strategic expansion into the high-need area of renal disorders. The study is being conducted in collaboration with Mayo Clinic expert DrFouad Chebib.

ADPKD, a prevalent genetic disorder characterized by the growth of numerous kidney cysts, affects about 1 in 400 to 1,000 people worldwide. The disease progressively impairs kidney function, often leading to kidney failure. Curren...